Clinical trials: Negative Symptoms in Schizophrenia, active
Schizoaffecitve Disorder, Schizophrenia and Schizoaffective Disorder
Combination Therapy of Deferiprone and N-Acetylcysteine for Treating Negative Symptoms in Schizophrenia
In following guidelines for studying negative symptoms in schizophrenia, 60 patients aged 18-40, diagnosed with schizophrenia or schizoaffective disorder during the last ten years, will receive a combination of the iron chelator…
- Conditions
- Schizoaffecitve Disorder, Schizophrenia and Schizoaffective Disorder, Schizophrenia and Predominant Negative Symptoms
- Trial name
- IronMan (NCT07759895)
- Testing
- Deferiprone (DFP), N-Acetyl Cysteine (NAC)
- Where
- 2 sites in Israel
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Amit Lotan
Schizophrenia, Negative Symptoms of Schizophrenia
Berberine in Treating Negative Symptoms of Schizophrenia: Clinical Efficacy and Mechanisms
"Negative" symptoms are a major challenge for people with schizophrenia (SZ) and are a key reason why they struggle with everyday functioning.
- Trial name
- NCT07356765
- Testing
- Berberine
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Tianjin Anding Hospital
Schizophrenia and Predominant Negative Symptoms
Accelerated Neuromodulation Therapy for Negative Symptoms of Schizophrenia
The goal of this clinical trial is to learn if an accelerated form of neuromodulation therapy can help improve negative symptoms of schizophrenia.
- Trial name
- TMSNS (NCT07428460)
- Testing
- Neuronavigated Intermittent Theta Burst Stimulation, BEAM-F3 Intermittent theta burst stimulation
- Where
- 3 sites in Canada
- Volunteers
- 75 people
- Sponsor
- Douglas Mental Health University Institute
Negative Symptoms of Schizophrenia
Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications
Evaluate the efficacy, as well as safety and pharmacokinetics, of Roluperidone in improving the negative symptoms of schizophrenia in adult subjects in Phase A of study, followed by Phase B of study to evaluate the relapse rate…
- Trial name
- NCT07565428
- Testing
- Roluperidone, risperidone, aripiprazole
- Where
- 13 sites in United States
- Volunteers
- 380 people
- Sponsor
- Minerva Neurosciences
Negative Symptoms in Schizophrenia, Brain Stimulation Intervention
Combining HD-tDCS and iTBS in Treating Negative Symptoms of Schizophrenia
Dysfunction of the dorsolateral prefrontal cortex (DLPFC) is central to the persistence of negative symptoms in schizophrenia. Both HD-tDCS and iTBS targeting the left DLPFC have shown therapeutic benefit.
- Trial name
- NCT07680959
- Testing
- active iTBS followed by active HD-tDCS
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- Tri-Service General Hospital (TSGH)
Schizophrenia, Cognitive Symptoms
PQQ for Cognitive and Negative Symptoms
Schizophrenia is a complex mental disorder characterized by a range of symptoms, including negative symptoms and cognitive impairments.
- Conditions
- Schizophrenia, Cognitive Symptoms, Negative Symptoms
- Trial name
- NCT07393464
- Testing
- Pyrroloquinoline quinone (PQQ)
- Volunteers
- 70 people
- Sponsor
- Tianjin Anding Hospital
Negative Symptoms With Primary Psychotic Disorder, Schizophrenia
rTMS Add on Value for Amelioration of Negative Symptoms of Schizophrenia
Treatment of depression with repetitive transcranial magnetic stimulation (rTMS) has shown high evidence using high-frequency left dorsolateral prefrontal cortex (DLPFC) stimulation.
- Trial name
- RADOVAN (NCT04318977)
- Testing
- high-frequency rTMS, TBS
- Where
- 4 sites in Czechia, Germany
- Volunteers
- 62 people
- Sponsor
- University of Regensburg
Negative Symptoms in Schizophrenia, Cognition Function
tACS to Improve Negative Symptoms & Cognition in Long-term Hospitalized Schizophrenia Patients.
This study aims to evaluate the efficacy of transcranial alternating current stimulation (tACS) on negative symptoms and cognitive function in long-term hospitalized patients with schizophrenia.
- Trial name
- NCT07074704
- Testing
- Hi-tACS
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Tongji University
Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis, Hallucinations and Delusions Associated With Parkinson Disease Psychosis
A Phase 1, MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03017
This is a phase 1，randomized, double-blind, placebo-controlled, MAD study to evaluate the safety, tolerability and pharmacokinetics of oral LPM526000133 Fumarate Capsules (LY03017) in healthy adult subjects
- Conditions
- Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis, Hallucinations and Delusions Associated With Parkinson Disease Psychosis, Negative Symptoms of Schizophrenia
- Trial name
- NCT06980207
- Testing
- LY03017
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Negative Symptoms in Schizophrenia, Schizophrenia Disorders
40 Hz Visual Stimulation as an Intervention in Schizophrenia
In schizophrenia, an abnormal reduction in neuronal gamma oscillations (30-100 Hz) is associated with negative symptoms such as cognitive dysfunction.
- Conditions
- Negative Symptoms in Schizophrenia, Schizophrenia Disorders, Schizoaffective Disorder
- Trial name
- GammaSZ (NCT06907420)
- Testing
- Visual stimulation
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Technical University of Munich
Alzheimer's Disease Psychosis, Parkinson Disease Psychosis
Effect of Food and Age on the Pharmacokinetics of LY03017
This study consists of 2 parts. Part A is a randomized, open-label, 2-period, crossover study to evaluate the food effect of LY03017 in healthy adults.
- Conditions
- Alzheimer's Disease Psychosis, Parkinson Disease Psychosis, Negative Symptoms of Schizophrenia
- Trial name
- NCT06793995
- Testing
- LY03017
- Where
- China
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Schizophrenia, Negative Symptoms in Schizophrenia
Treatment of Negative Symptoms of Schizophrenia by rTMS
The purpose of this study is to assess the effectiveness of rTMS on the negative symptoms of schizophrenia in real conditions. It will also provide a regulatory framework to rTMS treatments under these conditions.
- Trial name
- SN RENAT (NCT06595654)
- Testing
- repetitive Transcranial Magnetic Stimulation
- Where
- France
- Volunteers
- 124 people
- Sponsor
- Centre hospitalier de Ville-Evrard, France
Schizophrenia, Negative Symptoms in Schizophrenia
Validation of the Lithuanian Version of the BNSS, CDSS, and the SCoRS
This study aims to validate the Lithuanian version of the Brief Negative Symptoms Scale, Calgary Depression Scale for Schizophrenia, and Schizophrenia Cognition Rating Scale in a Lithuanian sample.
- Conditions
- Schizophrenia, Negative Symptoms in Schizophrenia, Depressive Symptoms Due to Primary Psychotic Disorder (Diagnosis), Cognitive Deficit
- Trial name
- NCT06278532
- Testing
- Brief Negative Symptoms Scale, The Calgary Depression Scale for Schizophrenia, The Schizophrenia Cognition Rating Scale
- Where
- 2 sites in Lithuania
- Volunteers
- 200 people
- Sponsor
- Lithuanian University of Health Sciences
Negative Symptoms in Schizophrenia
Metacognitive Training for Negative Symptoms
There is a clear rationale for developing interventions targeting negative symptoms of schizophrenia as these are a stronger indicator of current and future functioning than positive symptoms and because they respond poorly to…
- Trial name
- NCT06127004
- Testing
- Metacognitive Training for Negative Symptoms (MCT), Supportive Counselling
- Where
- Sweden
- Volunteers
- 90 people
- Sponsor
- Sormland County Council, Sweden
Schizophrenia, Persistent Negative Symptoms
Stratifying Psychoses for Personalized REpetitive TMS in Persistent NEgative Symptoms Alleviation
In its 2012's release guideline on therapy for schizophrenia, the EMA joined the FDA to acknowledge primary and persistent negative symptoms (PNS) as an unmet need in the treatment of schizophrenia.
- Conditions
- Schizophrenia, Persistent Negative Symptoms, Progressive Periodic Catatonia, Aviation
- Trial name
- SP-RENESA (NCT06184165)
- Testing
- Personalized rTMS
- Volunteers
- 160 people
- Sponsor
- University Hospital, Strasbourg, France